X0609 4 2026-06-26 0001815442 Kymera Therapeutics, Inc. KYMR 0001451612 Booth Bruce false C/O KYMERA THERAPEUTICS, INC. 500 NORTH BEACON STREET, FLOOR 4 WATERTOWN MA 02472 true false false false 1 Common Stock 2026-06-26 4 S 0 28296 107.57 D 2834055 I See footnote Common Stock 2026-06-26 4 S 0 231007 108.14 D 2603048 I See footnote Common Stock 2026-06-26 4 S 0 32624 109.79 D 2570424 I See footnote Common Stock 2026-06-26 4 S 0 11277 110.49 D 2559147 I See footnote Common Stock 2026-06-26 4 S 0 10366 111.51 D 2548781 I See footnote Common Stock 2026-06-26 4 S 0 555 112.49 D 2548226 I See footnote Common Stock 2026-06-26 4 S 0 14913 113.97 D 2533313 I See footnote Common Stock 2026-06-26 4 S 0 27951 114.94 D 2505362 I See footnote Common Stock 2026-06-26 4 S 0 6821 115.69 D 2498541 I See footnote Common Stock 2026-06-26 4 S 0 12181 117.09 D 2486360 I See footnote Common Stock 2026-06-26 4 S 0 22046 117.85 D 2464314 I See footnote Common Stock 2026-06-26 4 S 0 12390 118.66 D 2451924 I See footnote Common Stock 2026-06-26 4 S 0 3958 107.57 D 525760 I See footnote Common Stock 2026-06-26 4 S 0 32402 108.14 D 493358 I See footnote Common Stock 2026-06-26 4 S 0 4562 109.79 D 488796 I See footnote Common Stock 2026-06-26 4 S 0 1579 110.49 D 487217 I See footnote Common Stock 2026-06-26 4 S 0 1442 111.51 D 485775 I See footnote Common Stock 2026-06-26 4 S 0 78 112.49 D 485697 I See footnote Common Stock 2026-06-26 4 S 0 2083 113.97 D 483614 I See footnote Common Stock 2026-06-26 4 S 0 3896 114.94 D 479718 I See footnote Common Stock 2026-06-26 4 S 0 952 115.69 D 478766 I See footnote Common Stock 2026-06-26 4 S 0 1701 117.09 D 477065 I See footnote Common Stock 2026-06-26 4 S 0 3069 117.85 D 473996 I See footnote Common Stock 2026-06-26 4 S 0 1729 118.66 D 472267 I See footnote Common Stock 2026-06-29 4 S 0 5471 105.78 D 2446453 I See footnote Common Stock 2026-06-29 4 S 0 14613 106.63 D 2431840 I See footnote Common Stock 2026-06-29 4 S 0 19093 107.76 D 2412747 I See footnote Common Stock 2026-06-29 4 S 0 848 105.78 D 471419 I See footnote Common Stock 2026-06-29 4 S 0 2318 106.63 D 469101 I See footnote Common Stock 2026-06-29 4 S 0 3024 107.76 D 466077 I See footnote This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.995 to $107.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2), (4) through (14), and (16) through (18). These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.00 to 108.9725 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.02 to $110.0166 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.02 to $111.0075 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.1057 to $111.9188 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.1843 to $113.0139 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.2614 to $114.246 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.2766 to $115.2672 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.27 to $116.2626 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.2731 to $117.2668 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.2728 to $118.2599 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.2717 to $119.035 inclusive. The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.015 to $106.0145 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.0271 to $106.96 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.03 to $108.0293 inclusive. Due to the 30 line limitation in Table I, this report is being filed across two forms. This is the first of two filings. /s/ Ommer Chohan, Attorney-in-Fact 2026-06-30